Abstract
The natural history of tuberculosis (TB) is characterized by a large inter-individual outcome variability after exposure to Mycobacterium tuberculosis. Specifically, some highly exposed individuals remain resistant to M. tuberculosis infection, as inferred by tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). We performed a genome-wide association study of resistance to M. tuberculosis infection in an endemic region of Southern Vietnam. We enrolled household contacts (HHC) of pulmonary TB cases and compared subjects who were negative for both TST and IGRA (n=185) with infected individuals (n=353) who were either positive for both TST and IGRA or had a diagnosis of TB. We found a genome-wide significant locus on chromosome 10q26.2 with a cluster of variants associated with strong protection against M. tuberculosis infection (OR=0.42, 95%CI 0.35-0.49, P = 3.71×10−8, for the genotyped variant rs17155120). The locus was replicated in a French multi-ethnic HHC cohort and a familial admixed cohort from a hyper-endemic area of South Africa, with an overall OR for rs17155120 estimated at 0.50 (95%CI 0.45-0.55, P = 1.26×10−9). The variants are located in intronic regions and upstream of C10orf90, a tumor suppressor gene which encodes an ubiquitin ligase activating the transcription factor p53. In silico analysis showed that the protective alleles were associated with a decreased expression in monocytes of the nearby gene ADAM12 which could lead to an enhanced response of Th17 lymphocytes. Our results reveal a novel locus controlling resistance to M. tuberculosis infection across different populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the French Foundation for Medical Research (FRM) (EQU201903007798; FDM20170637664 to J.Q.), the Programme Hospitalier de Recherche Clinique (AOR-04-003); the Legs Poix (Chancellerie des Universites de Paris), the French National Research Agency (ANR) under the "Investments for the future" program (grant ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the TBPATHGEN project (ANR-14-CE14-0007-01), the SCOR Corporate Foundation for Science, the Rockefeller University, the Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Paris, the St. Giles Foundation, the Canadian Institutes of Health Research (CIHR, FDN-143332) and the Sequella/Aeras Global Tuberculosis Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Signed informed consent was obtained from all the participants, and from the parents of enrolled minors. The study was approved by the regulatory authorities in Binh Duong, Vietnam (1366/UBND-VX), the Research Ethics Board of McGill University Health Centre, Montreal, Canada (06-030 GEN, 2007-859), the French Consultative Committee for Protecting Persons in Biomedical Research of Henri Mondor Hospital (Creteil, France) and the Stellenbosch University Health Research Ethics Committee (Tygerberg, South Africa).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
GWAS summary statistics are available at: 10.5281/zenodo.3942126
